News

Halozyme’s net income was $3.12m, or $0.03 per diluted share, compared to net loss of $12.15m, or $0.13 loss per diluted share, for the same period in 2010.

The increase in revenues primarily reflects gains in sales of the company’s products and services from its API, contract research and manufacturing and peptides synthesis businesses. Neuland Labs

In the study, ICR researchers have investigated DNA of women from 911 families with breast and ovarian cancer and compared differences in DNA with a control group of

P&G’s net earnings were $2.51bn for the fourth quarter ended 30 June 2011, compared to $2.19bn, for the same period in 2010. The company’s operating income was $3.29bn,

Inovio Pharma’s net loss was $2.84m or $0.02 loss per diluted share, compared to $7.61m, or $0.07 per diluted share, for the same period in 2010. The company’s

The Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity’s (NDO) decision is supported by the results of Phase III programme evaluating

The company’s loss from operations for the second quarter of 2011 was $6.28m, compared to $5.36m for the same period in 2010. For the six months ended 30

AZ-004 is indicated as a treatment of agitation in patients with schizophrenia or bipolar disorder. In the original CRL, the Center for Drug Evaluation and Research of FDA

The new name aligns with the company’s core technology – transdermal absorption of pharmaceutical agents. Promescent, which employs a proprietary, eutectic mixture of lidocaine and other compounds, delivers